No patients were prescribed ARNI and ivabradine at both discharge and the 1-year follow-up as these drugs were not approved in Japan at the time, and sodium-glucose cotransporter 2 inhibitors were only approved for patients with diabetes during the study period; these differences may have influenced the results. This evidence concerns the gene SLC5A2 and diabetes mellitus.